Contrasting Biostar Pharmaceuticals (OTCMKTS:BSPM) and Siga Technologies (NASDAQ:SIGA)

Biostar Pharmaceuticals (OTCMKTS:BSPM) and Siga Technologies (NASDAQ:SIGA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Biostar Pharmaceuticals and Siga Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Siga Technologies	$94.57 million	3.00	$23.28 million	$0.27	14.63

Siga Technologies has higher revenue and earnings than Biostar Pharmaceuticals.

Institutional and Insider Ownership

55.4% of Siga Technologies shares are owned by institutional investors. 17.2% of Biostar Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Biostar Pharmaceuticals and Siga Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostar Pharmaceuticals	N/A	N/A	N/A
Siga Technologies	21.58%	10.60%	8.94%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Biostar Pharmaceuticals and Siga Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostar Pharmaceuticals	0	0	0	0	0.00
Siga Technologies	0	1	0	0	2.00

Given Biostar Pharmaceuticals’ higher probable upside, equities analysts plainly believe Biostar Pharmaceuticals is more favorable than Siga Technologies.

Volatility & Risk

Biostar Pharmaceuticals has a beta of 67.71, suggesting that its share price is 6,671% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Summary

Siga Technologies beats Biostar Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Biostar Pharmaceuticals

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.